Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that affects women of reproductive age. Our company is at the forefront of PCOS drug and therapy development, offering a comprehensive range of services aimed at addressing the various aspects of this condition.
Overview of Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is a multifactorial disorder that affects approximately 10% of women worldwide. Elevated levels of androgens, such as testosterone, contribute to the characteristic symptoms of PCOS, including hirsutism (excessive hair growth) and acne. Insulin resistance, a condition where the body's cells become less responsive to insulin, is commonly observed in PCOS cases and can lead to metabolic disturbances, such as obesity and type 2 diabetes. Ovarian dysfunction, characterized by the presence of multiple cysts on the ovaries, disrupts the normal ovulation process, leading to irregular menstrual cycles and infertility.
Fig.1 Pathophysiology and characteristics of polycystic ovary syndrome (PCOS). (Singh S., et al., 2023)
Therapeutics Development for Polycystic Ovary Syndrome
There are a growing number of emerging therapeutic options for polycystic ovary syndrome (PCOS).
| Name | CAS Number | Targets | Status | Phase |
|---|---|---|---|---|
| Analgesics | -- | Nav1.7 | Unknown | Phase 2 |
| Acetylcarnitine | 3040-38-8 | CRAT | Approved | Phase 2 |
| Acarbose | 56180-94-0 | Alpha-amylase inhibitors | Approved | Phase 4 |
| Alogliptin | 850649-61-5 | DPP-4 | Approved | Phase 4 |
| Anastrozole | 120511-73-1 | Aromatase | Approved | Unknown phase |
Our Services
At our company, we are dedicated to developing diagnostics and innovative therapies for polycystic ovary syndrome. With a focus on emerging therapeutics, we aim to address the complex nature of PCOS from multiple angles. To further explore our exceptional therapy development services, we invite you to click on the links below.
Developing reliable animal models and in vitro models is critical for evaluating the efficacy of potential therapeutics. Our company has extensive expertise in developing PCOS animal models, including rodent models and non-human primate models, that accurately recapitulate the hormonal imbalances, ovarian dysfunction, and metabolic disturbances observed in PCOS cases. Furthermore, we specialize in the development of in vitro models, such as cell culture systems and organoids, which allow for the investigation of specific cellular and molecular processes involved in PCOS.
One approach to studying polycystic ovary syndrome (PCOS) involves direct hormonal interventions in animal models. Our team develops polycystic ovary syndrome animal models using techniques such as androgen administration, insulin resistance induction, and gonadotropin disturbances.
Direct Hormonal Interventions Induced Animal Models
Indirect hormonal perturbations can also contribute to the development of PCOS animal models. Through the manipulation of signaling pathways, such as the insulin and glucose metabolism pathways, our team can induce hormonal imbalances that mirror the characteristics of polycystic ovary syndrome (PCOS).
Indirect Hormonal Perturbations Induced Animal Models
Our company recognizes the importance of diet-mediated animal models in studying polycystic ovary syndrome (PCOS) and offers specialized services in this area. For example, high-fat or high-sugar diets are commonly used to induce metabolic disturbances and reproductive abnormalities.
Diet-Mediated PCOS Animal Models
Environmental factors can significantly influence PCOS development and progression. By exposing animals to environmental factors such as endocrine disruptors, stressors, or altered light-dark cycles, we can mimic the environmental conditions that may contribute to PCOS.
Environmental Changes Induce PCOS Animal Models
Our company specializes in developing animal models using chemicals that induce PCOS-like phenotypes. Chemicals such as d-galactose, monosodium l-glutamate (MSG), bisphenol A (BPA), tributyltin chloride (TBT), and letrozole have been shown to induce PCOS-like symptoms in mice and rats.
Chemically Induced PCOS Animal Models
Our team develops cell-based models using ovarian granulosa cells, theca cells, and adipocytes to study hormone production, insulin resistance, and lipid metabolism in PCOS. Moreover, we offer state-of-the-art organoid model development services to recreate the complex tissue architecture and functionality of the ovary.
In Vitro Models
Our preclinical research services encompass a wide range of studies aimed at evaluating the safety, efficacy, and mechanism of action of potential PCOS therapies. In addition to the extensive array of services and models discussed earlier, our company excels in creating personalized solutions and designing disease models that are precisely tailored to your specific needs. We take immense pride in our capacity to adapt and customize our offerings to cater to the individual requirements of each client. If our comprehensive range of services has captured your interest, we wholeheartedly urge you to reach out to us without any hesitation.
References
- Singh S., et al. "Polycystic ovary syndrome: etiology, current management, and future therapeutics." Journal of Clinical Medicine 12.4 (2023): 1454.
- McCartney Christopher R., and John C. Marshall. "Polycystic ovary syndrome." New England Journal of Medicine 375.1 (2016): 54-64.